These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37233443)
1. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma. Hu A; Tang K; Liu J; Han X; Chen Q Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443 [TBL] [Abstract][Full Text] [Related]
2. Role of Prognostic Marker Wang WH; Ma CG; Cui YS; Bai BY; Sheng ZM; Liu J; Li A; Zhang BG Biomed Environ Sci; 2023 Sep; 36(9):862-868. PubMed ID: 37803898 [TBL] [Abstract][Full Text] [Related]
3. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches. Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S PeerJ; 2023; 11():e16166. PubMed ID: 37790630 [TBL] [Abstract][Full Text] [Related]
4. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. Fan K; Zhang BH; Han D; Sun YC BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494 [TBL] [Abstract][Full Text] [Related]
5. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis. Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150 [TBL] [Abstract][Full Text] [Related]
7. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
8. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities]. Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328 [TBL] [Abstract][Full Text] [Related]
9. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma. Wei S; Xing J; Lu K; Wang K; Yu W Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219 [TBL] [Abstract][Full Text] [Related]
10. NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden. Li Z; Zheng Y; Wu Z; Zhuo T; Zhu Y; Dai L; Wang Y; Chen M Medicine (Baltimore); 2023 Jan; 102(3):e32686. PubMed ID: 36701707 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
12. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. Guo L; Li X; Liu R; Chen Y; Ren C; Du S Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817 [TBL] [Abstract][Full Text] [Related]
13. Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma. Hu S; Wang F; Yang J; Xu X Math Biosci Eng; 2023 Sep; 20(10):18063-18082. PubMed ID: 38052548 [TBL] [Abstract][Full Text] [Related]
14. High Expression of Chen Y; Zhou M; Gu X; Wang L; Wang C Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850 [TBL] [Abstract][Full Text] [Related]
15. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma. Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804 [TBL] [Abstract][Full Text] [Related]
16. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining. Liu J; Hou S; Wang J; Chai Z; Hong X; Zhao T; Sun Z; Bai L; Gao H; Gao J; Chen G Oxid Med Cell Longev; 2020; 2020():8847226. PubMed ID: 33414898 [TBL] [Abstract][Full Text] [Related]
17. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Jing Y; Mao Z; Zhu J; Ma X; Liu H; Chen F Int Immunopharmacol; 2023 Sep; 122():110605. PubMed ID: 37451021 [TBL] [Abstract][Full Text] [Related]
18. ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis. Chen B; Shen K; Zhang T; Gao WC Medicine (Baltimore); 2023 Sep; 102(36):e35013. PubMed ID: 37682172 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma. Zhang H; Lin J; Yahaya BH J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298 [TBL] [Abstract][Full Text] [Related]
20. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma. Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]